The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib

These results demonstrate a survival benefit with the addition of LRTx to sorafenib for patients with advanced HCC. These findings should prompt a prospective clinical trial to further assess the role of LRTx in patients with advanced HCC.